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The Journal of Immunology
Mast Cells Control the Expansion and Differentiation of
IL-10–Competent B Cells
Francesca Mion,* Federica D’Inca`,* Luca Danelli,* Barbara Toffoletto,*
Carla Guarnotta,† Barbara Frossi,* Alessia Burocchi,‡ Alice Rigoni,‡ Norbert Gerdes,x
Esther Lutgens,x,{ Claudio Tripodo,† Mario P. Colombo,‡ Juan Rivera,‖ Gaetano Vitale,*,1
and Carlo E. Pucillo*,1
The discovery of B cell subsets with regulatory properties, dependent on IL-10 production, has expanded our view on the mech-
anisms that control inflammation. Regulatory B cells acquire the ability to produce IL-10 in a stepwise process: first, they become
IL-10 competent, a poised state in which B cells are sensitive to trigger signals but do not actually express the Il-10 gene; then, when
exposed to appropriate stimuli, they start producing IL-10. Even if the existence of IL-10–competent B cells is now well estab-
lished, it is not yet known how different immune cell types cross talk with B cells and affect IL-10–competent B cell differentiation
and expansion. Mast cells (MCs) contribute to the differentiation and influence the effector functions of various immune cells,
including B lymphocytes. In this study, we explored whether MCs could play a role in the expansion of IL-10–competent B cells
and addressed the in vivo relevance of MC deficiency on the generation of these cells. We show that MCs can expand IL-10–
competent B cells, but they do not directly induce IL-10 production; moreover, the absence of MCs negatively affects IL-10–
competent B cell differentiation. Noteworthy, our findings reveal that the CD40L/CD40 axis plays a significant role in MC-driven
expansion of IL-10–competent B cells in vitro and highlight the importance of MC CD40L signaling in the colon. The Journal of
Immunology, 2014, 193: 4568–4579.
M
ast cells (MCs) are particularly abundant at the sur-
faces of contact between the body and the external
environment where they act as “sentinels” of tissue
and immune homeostasis (1). MCs function at the crossroad be-
tween innate and adaptive immunity, exerting both effector and
immunoregulatory roles, depending on their activation status and
on the immunological context (2). MCs express a broad array of
soluble and membrane-bound molecules that enable the cross talk
with many immune cells of which they influence phenotype and
function (3, 4). MCs prime and regulate adaptive responses by
either inducing effector T cells or modulating regulatory T cell
suppression (5). In contrast with the well-defined role for MCs in
regulating T cell function, little is known about the interaction of
MCs with B cells. Although the B–MC interaction has long been
considered as likely and worthy of investigation (6, 7), only re-
cently has this line of research been more fully explored.
B lymphocytes were traditionally considered effector cells given
their ability to produce Abs. Nonetheless, recent findings from
several groups revealed the existence of phenotypically diverse
B cell subsets with a regulatory suppressive function in various
models of chronic inflammation and autoimmune disease (8). The
most widely studied and best understood mechanism by which
B lymphocytes accomplish immunosuppression is through secre-
tion of IL-10 (9). In mice, B cells that are competent to express
Il-10 are found in different tissues, although at very low fre-
quencies. The majority of these cells do not produce detectable
cytoplasmic IL-10, but they do so after 5 h of in vitro stimulation
with LPS, PMA, and ionomycin (10). Therefore, the subset of
B cells capable of producing IL-10 after this in vitro stimulation
has been labeled as IL-10 competent. Several studies have shown
that upon activation, IL-10–competent B cells exert regulatory
suppressive functions (11), and that stimulation through CD40 is
essential for their induction (12).
We have previously demonstrated that MCs can enhance the
proliferation and survival of B cells, and drive their functional
differentiation toward IgA-secreting plasma cells through CD40L
stimulation and IL-6 release (13). In light of these findings, we
hypothesized that, similar to their interaction with T cells (5), MCs
may selectively regulate distinct B cell subsets. In this article, we
demonstrate that MCs can expand IL-10–competent B cells and that
this expansion is reduced by impairing the CD40L/CD40 axis.
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Moreover, the analysis of CD19+IL-10+ cells in different organs of
wild-type (WT) and MC-deficient mice revealed that the absence of
MCs negatively affects IL-10–competent B cell differentiation, and
this can be seen as a very relevant observation in the context of
immunologically mediated inflammatory reactions.
Materials and Methods
Mice
Female C57BL/6 (B6) mice were from Harlan Laboratories. C57BL/
6-KitW-sh/W-sh (KitW-sh) mice were from The Jackson Laboratory and were
maintained under specified pathogen-free conditions at the animal facility
of Fondazione IRCCS INT, Milan, Italy, in collaboration with the group of
M. Colombo. Four- to 6-wk-old female KitW-sh mice were reconstituted by
i.p. injection of 5 3 106 in vitro differentiated bone marrow MCs derived
from B6 or Cd40l2/2 mice. Experiments were initiated 8–10 wk later. All
animal experiments were performed in accordance with the animal care
and use committees of the respective institutes.
Dextran sodium sulfate–induced colitis
To induce colon inflammation, we administered 1.5% dextran sodium sulfate
(DSS; m.w. 40.000–50.000; Affymetrix) to WT and KitW-sh mice in place of
normal drinking water for 10 d. Inflammation progression was monitored up
to 7 d after DSS withdrawal (day 17). To perform histological analyses, we
dissected colons from mice at three different time points: steady-state (day
0), acute inflammation (day 10), and recovery from inflammation (day 17).
Abs
Fluorescence-conjugated Abs to CD1d (1B1), CD19 (6D5), CD40L (MR1),
and IL-10 (JES5-16E3) were from BioLegend. PE-Cy7 anti-CD5 (53-7.3)
and allophycocyanin anti-CD9 (KMC8) were from eBioscience. Allo-
phycocyanin anti-CD21/CD35 (7G6) was from BD Pharmingen; Alexa
Fluor 647 anti-CD23 (B3B4) was from AbD Serotec. Alexa 488 goat anti-
rat and Alexa 568 goat anti-mouse Abs were from Molecular Probes.
Unconjugated anti-CD45RA (MEM 56) and anti–IL-10 (JES5-16E3) Abs
were, respectively, from Merck Millipore and Novus Biologicals. Anti-
Hsp60 (LK-2) and anti-Hsc70 (1B5) Abs were purchased from Abcam,
whereas the anti–TATA-binding protein (TBP, clone 58C9) Ab was from
Sigma-Aldrich and the anti-ATP5B (3D5) Ab from Santa Cruz. Ascites
containing the anti-CD40L (MR1) Ab were a gift of M. Colombo.
Cell preparation
Purified splenic B cells were obtained from 6- to 12-wk-old B6 mice as
previously described (14). Bone marrow–derived MCs (BMMCs) were ob-
tained by in vitro differentiation of bone marrow cells taken from femurs of
B6 WT or Cd40l2/2 mice as previously described (15). Lymph node cells
were purified from either axillary or inguinal lymph nodes by gently dis-
rupting the lymph node in PBS using the sterile plunger of a 1-ml syringe.
Peritoneal cells were obtained injecting cold PBS supplemented with 3%
FBS in the peritoneal cavity and dislodging any attached cell by massaging
the peritoneum. The peritoneal B cell population was enriched by per-
forming an adhesion step of at least 1 h in a six-well flat-bottom culture plate
and by collecting only the nonadherent cells. Colonic lamina propria (LP)
cells were isolated as described previously (16), through two sequential
incubations of 30 min each with, respectively, 1.5 mg/ml Dispase (Life
Technologies) and 1.0 mg/ml Dispase plus 1.5 mg/ml collagenase type II
(Life Technologies). The obtained cell population was enriched in B and
T lymphocytes (B cells were 20% of the enriched lymphocyte population)
through Percoll gradient (45–72%) centrifugation.
B–MC coculture conditions
Purified splenic B cells were cultured for 48 h with an equal number of IgE-
sensitized or nonsensitized MCs, in the presence or absence of 100 ng/ml
DNP–human serum albumin (Sigma-Aldrich). To study the role of MCs on
B lymphocytes from the peritoneum and colonic LP, we cultured 0.63 106
MCs with an equal number of total peritoneal or colonic cells, enriched in
B lymphocytes as described earlier. To evaluate the role of the CD40L/
CD40 axis, we added an ascites containing the anti-CD40L blocking Ab
to culture medium at 50 mg/ml and maintained it for all 48 h of culture.
In some experiments, B cells and MCs were separated by a transwell
(Corning Costar) with pores of 0.4 mm. A total of 0.6 3 106 B cells was
cultured in the bottom chamber in 0.7 ml medium while 0.2 3 106 MCs
were placed in the top chamber, in a final volume of 0.2 ml. For prolif-
eration assays, B cells were stained with Cell Proliferation Dye eFluor 670
(CPD; eBioscience) before coculture with MCs for 72 h.
Detection of intracellular and secreted IL-10
For immunofluorescent staining of IL-10, cells were resuspended in me-
dium containing 10 mg/ml LPS, 50 ng/ml PMA, 500 ng/ml ionomycin,
2 mMmonensin (all from Sigma-Aldrich) and cultured for 5 h at 37˚C. The
protocol for intracellular staining was as described previously (10). In
certain experiments, Alexa Fluor 647 anti-CD23, FITC anti-CD5, allo-
phycocyanin anti-CD21/CD35 and Alexa Fluor 647 anti-CD23 or PE-Cy7
anti-CD5 and Pacific Blue anti-CD1d were used to assess the expression of
surface markers other than CD19. Stained samples were acquired on
FACScan (BD Biosciences), FACSCalibur (BD Biosciences), or Cyan ADP
nine-color cytometer (DakoCytomation). Data were analyzed with FlowJo
software.
IL-10 levels in cell supernatants were quantified by ELISA. A total of
0.6 3 106 B cells and MCs was seeded, either alone or together, in 0.6 ml
medium and cultured for 48 h. The mouse IL-10 ELISA Ready-SET-Go kit
(eBioscience) was used, following manufacturer’s instructions.
Purification and analysis of exosomes from cell culture
supernatants
A total of 5 3 106 B cells and MCs was cultured either alone or together
in 5 ml medium for 48 h. Culture media were collected and centrifuged
at 300 3 g for 10 min. Cleared supernatants were incubated with 1 ml
ExoQuick-TC Exosome Precipitation Solution (System Biosciences)
overnight (o/n) at 4˚C for precipitation. The exosome-containing pellet was
resuspended in PBS and stored at 280˚C until use for analysis. For flow
cytometry experiments, isolated exosomes were incubated with 4-mm di-
ameter aldehyde/sulfate latex beads (Interfacial Dynamics; 10 ml in 0.3 ml
PBS), o/n, at room temperature, under gentle movement. Samples were
saturated with 1 M glycine, washed, and stained with specific Abs. Sam-
ples were acquired on FACSCalibur and analyzed by Summit v4.3 soft-
ware (Dako Cytomation). For Western blot experiments, exosomes were
lysed in radioimmunoprecipitation assay buffer (25 mM Tris-HCl pH 7.6,
150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS)
and mixed with Laemmli buffer. Protein extracts were separated on 12%
SDS-PAGE, samples were transferred onto nitrocellulose membranes, and
Western blot analyses were performed using specific anti-Hsp60, anti-
Hsc70, anti-TBP, or anti-ATP5B Abs. HRP-conjugated secondary Abs
were revealed using chemiluminescence substrate (Pierce). Blots were
captured by using a ChemiDoc XRS imaging system (Bio-Rad), and sig-
nals were quantified with the instrument bundled densitometric software.
Real-time video microscopy and conjugate formation
evaluation
The formation of MC–B cell conjugates in real time was analyzed by time-
lapse epiluminescent microscopy as previously described (17). At different
time points the number of MCs in contact with B cells was counted and the
percentage of B-conjugated MCs over total MCs per field was calculated.
Immunofluorescence microscopy
Tissue samples were fixed in 10% buffered formalin and paraffin embedded.
For immunofluorescence analysis, tissue sections were deparaffinized with
xylene and rehydrated to water through a graded alcohol series. High-
temperature Ag unmasking was performed using citrate buffer pH 6
(Novocastra) in a water bath at 98˚C for 30 min. Subsequently, the sections
were brought to room temperature and washed in PBS. After Fc blocking
using a specific protein block (Novocastra), samples were incubated o/n
with rat anti-mouse IL-10 Ab followed by the Alexa 488 goat anti-rat Ab.
Subsequently, slides were incubated with anti-mouse CD45RA Ab and
marked by the Alexa 568 goat anti-mouse Ab.
Statistical analysis
Experimental data are shown as means6 SEM. Unpaired or paired Student
t tests (Prism GraphPad Software) were used to analyze the results for
statistical significance. The p values ,0.05 were considered significant.
Results
MCs promote the expansion in vitro of IL-10–competent B cells
To assess the ability of MCs to influence the expansion of IL-10–
competent B cells, we cocultured murine BMMCs and splenic
B cells at a 1:1 ratio for 48 h. To induce cytoplasmic IL-10 pro-
duction in IL-10–competent B cells and block protein secretion,
we added a mixture of LPS, PMA, ionomycin, and monensin
(LPIM) to the coculture 5 h before cell harvesting. Compared with
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freshly isolated B lymphocytes, the proportion of B cells com-
petent to express cytoplasmic IL-10 after LPIM stimulation was
significantly increased after coculture with MCs (Fig. 1A). Co-
culture of B lymphocytes with non–IgE-sensitized or IgE-Ag–
stimulated MCs increased the proportion of IL-10+ B cells to 8.4%
(60.9) and 7.1% (60.8), respectively, an ∼2.5-fold increase with
respect to the pre-coculture condition (2.9 6 0.2%). Both in
freshly purified B cells and in B-MC cocultures, no cells positively
stained for IL-10 were detected without the 5-h addition of LPS
plus PMA and ionomycin (Supplemental Fig. 1).
To test whether the observed increase of IL-10–competent
B cells might be driven through enhanced and selective prolifer-
ation induced by MCs, we labeled B lymphocytes with the CPD
and cocultured them with non–IgE-sensitized MCs for 72 h. As
shown in Fig. 1B, MCs induced the proliferation of both IL-10+
and IL-102 B cells. However, the IL-10–competent B cell pop-
ulation showed an enhanced proliferation profile compared with
the IL-102 counterpart.
Because IL-10 competence and production are differently reg-
ulated processes (18), we next evaluated whether MCs could en-
hance the secretion of IL-10 from B cells in a 48-h coculture
without the addition of LPIM during the last 5 h. B cells or MCs
alone released low and almost undetectable amounts of IL-10
when compared with B cells stimulated with LPS, which is
known to promote IL-10 secretion (10). As shown in Fig. 1C, the
secretion of IL-10 was not enhanced when MCs and B cells were
cocultured. The result of the ELISA experiment was confirmed by
the analysis of the Il-10 gene expression profile obtained by
assessing IL-10 mRNA levels in B cells cultured either alone or
with MCs (Supplemental Fig. 2).
Phenotypic markers of MC-induced, IL-10–competent B cells
IL-10–competent B cells share phenotypic markers with CD21hi
CD232IgMhiCD1dhi marginal zone (MZ) and CD21hiCD23+IgMhi
CD1dhi transitional two-MZ precursor (T2-MZP) B cells, but also
with CD5+ B-1a and CD1dhiCD5+ B10 cells (11, 19–21).
To address the phenotype of IL-10–competent splenic B cells
obtained after coculture with MCs, we analyzed B cells within
both the IL-10+ and the IL-102 gates for CD1d and CD5 ex-
pression, because their differential expression allows us to dis-
tinguish distinct subsets of regulatory B cells (Bregs) described in
the literature (11). IL-10–competent B cells induced by non–IgE-
sensitized MCs were found within all the four subsets defined by
the differential expression of the aforementioned markers. The
highest proportion of these cells (51.1 6 3.6%) expressed high
levels of CD1d and low levels of CD5, thus resembling the phe-
notype of MZ or T2-MZP B cells (Fig. 2A). Only a small pro-
portion of total IL-10+ B cells were CD1d+CD5+ (7.7 6 1.1%) or
CD1d2CD5+ (4.3 6 1.1%). In contrast, the majority of IL-102
cells expressed low levels of both CD1d and CD5.
Because CD21 and CD23 are commonly used to distinguish MZ
from follicular and transitional B cells (22, 23), we further ana-
lyzed the expression levels of these markers on IL-10+ B cells
after coculture with MCs. As shown in Fig. 2B, the majority of
IL-10+ B cells expressed high levels of CD19 and CD21 and were
CD23+, further supporting the evidence that these cells are phe-
notypically similar to T2-MZP B cells.
The CD40L/CD40 axis contributes to MC-driven expansion of
IL-10–competent B cells
Both cell–cell contacts and cytokines secreted by MCs could be
responsible for the expansion of IL-10–competent B cells. To test
the relative contribution of both components, we performed a co-
culture transwell assay. As shown in Fig. 3A, when the two
populations were physically separated, a partial but significant
decrease was observed in the proportion of IL-10+ B cells. The
coculture with non–IgE-sensitized MCs induced 8.1% (6 0.9) IL-
10–competent B cells, whereas only 6.7% (61.0) of the B cells
were IL-10+ in the presence of the transwell. Similar results were
seen when MCs were stimulated with IgE-Ag. These findings
suggest that cell contacts contribute to the expansion of IL-10–
competent B cells, but also imply that soluble factors are involved.
We next explored which membrane molecules might be involved
in promoting IL-10–competent B cell expansion. MCs express
several costimulatory molecules, many of which are known to
modulate B cell activation and function. CD40L is constitutively
expressed on the surface of MCs (Fig. 3B), and we previously
showed that its interaction with CD40 on B cells is important for
MC-driven proliferation of B cells and for their differentiation into
plasma cells (13).
To evaluate whether the CD40L/CD40 axis is involved in
the physical interaction between MCs and B cells, we observed
cell–cell interactions by real-time imaging. Time-lapse bright-
field video microscopy showed that MC–B cell conjugates were
formed after only few minutes of coculture (Fig. 3C). Interest-
ingly, when MCs were derived from Cd40l2/2 mice, the number
of conjugates was drastically reduced compared with WT MCs.
As soon as 1 min after coculture, the proportion of Cd40l2/2MCs
making contacts with B cells was 5-fold less than that of WT
MCs, and this defect in interaction continued for at least 20 min of
observation. These findings suggest that the presence of CD40L
on MCs is crucial for the formation of cell–cell contacts with
B cells.
Given the importance of the CD40L/CD40 axis in B–MC in-
teraction, we analyzed its contribution to the expansion of IL-10–
competent B cells. In the presence of an anti-CD40L blocking Ab,
a significant decrease in the proportion of CD19+IL-10+ cells was
observed (Fig. 3D). This reduction was ∼30% and occurred with
both non–IgE-sensitized and IgE-Ag–stimulated MCs. To further
validate these findings, we used Cd40l2/2 BMMCs to perform the
B–MC cocultures. As shown in Fig. 3E, in the presence of non–
IgE-sensitized or IgE-Ag–stimulated Cd40l2/2 MCs, the propor-
tion of CD19+IL-10+ cells was, respectively, 5.3 (6 1.2) and 4.8%
(6 1.3), ∼20% lower than for B lymphocytes incubated with WT
MCs.
CD40L-exosomes contribute to MC-driven expansion of
IL-10–competent B cells
In addition to the expression of cell-surface costimulatory mole-
cules, MCs produce exosomes (Fig. 4A), whose content is quite
heterogeneous (24, 25). It has been previously shown that MCs
can communicate with B cells through the secretion of these
small, diffusible vesicles that induce B cell proliferation and ac-
tivation (26, 27). Because CD40L is a prominent component of
MC-derived exosomes (27), the possible role of exosomes in the
expansion of IL-10–competent B cells was investigated.
MCs and B cells were cultured either alone or together for 48 h.
Exosomes were isolated from conditioned media (CM) and ana-
lyzed by flow cytometry. As shown in Fig. 4B, both MCs and
B cells released exosomes. As expected, CD9 (a characteristic
exosome marker) was detected on both MC- and B cell–exosomes,
whereas CD40L was found only on MC-secreted exosomes. In-
terestingly, supernatants from B–MC cocultures showed less de-
tectable exosomes, and those present did not express CD40L at the
levels seen in exosomes derived from cultures of MCs alone
(Fig. 4B). In light of these results, we quantified the proportion of
IL-10–competent B cells when B lymphocytes were cultured for
48 h with MC-CM in the presence or absence of an anti-CD40L
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FIGURE 1. MCs induce expansion of IL-10–competent B cells, but not IL-10 production. (A) IL-10–competent B cells were analyzed in freshly isolated
splenic B cells (B pre-coculture) and in B cells cultured for 48 h with either nonsensitized MCs (B+MC) or IgE-sensitized MCs stimulated with DNP (B+MC/
IgE-Ag). In all conditions, LPIM was added for the last 5 h of culture. Dot plots for one representative experiment are shown. CD19 versus Live/Dead plots
allow to identify viable B cells (B) and exclude both MCs, which are negative for CD19 staining, and dead cells that are positive for Live/Dead staining. Only
viable B cells were analyzed for IL-10 staining, and a perfectly matched isotype control (Rat IgG2b) was used to discriminate IL-10+ from IL-102 B cells. Bar
graphs indicate mean (6 SEM) percentages of IL-10+ cells among total B cells (n = 5). (B) B cells were labeled with CPD and cultured with MCs for 72 h, with
LPIM added during the last 5 h of coculture. Dot plots for one representative experiment are shown; the percentages of proliferating cells among both the IL-10+
and the IL-102 populations are indicated. Histograms represent CPD expression in IL-10+ and IL-102 B cells. Filled histograms represent CPD staining of total
unstimulated B cells. Data are representative of n = 3 experiments. (C) B cells, MCs, or B+MCs were cultured for 48 h with no addition of LPIM. IL-10
concentration in culture supernatants was assessed by ELISA. The same experiment was performed using IgE-Ag–stimulated MCs. B cells activated with 10
mg/ml LPS were used as control. Bar graphs indicate mean (6SEM) concentrations of n = 3 experiments. *p , 0.05, **p , 0.01.
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blocking Ab. Indeed, when B cells were cultured with non–IgE-
sensitized MCs supernatants, the proportion of CD19+IL-10+ cells
was 2.6-fold higher than that seen in the nontreated B cell pop-
ulation (Fig. 4C). When the anti-CD40L blocking Ab was added
to MC-CM and cultured with B cells, a significant reduction
(25%) in the proportion of CD19+IL-10+ cells was observed rel-
ative to B cells cultured in MC-CM.
MCs influence IL-10–competent B cell differentiation in vivo
Next, we explored in vivo whether MCs play a role in the dif-
ferentiation of IL-10–competent B cells. To do so, we used the
C57BL/6-KitW-sh/W-sh (KitW-sh) murine model of MC deficiency,
which enabled us to investigate whether the congenital deficiency
of MCs could affect the proportions of IL-10–competent B cells in
various lymphoid organs. We analyzed the percentage of IL-10–
competent B cells in the bone marrow, lymph nodes, peritoneum,
and spleen, which are all known to be important sites of B cell
differentiation, maturation, and activation, and we compared them
with control C57BL/6 (B6) mice. After stimulation with LPIM for
5 h, CD19+IL-10+ cells were found in all the organs studied of
both MC-deficient and -sufficient mice (Fig. 5). In the spleen, the
IL-10–competent B cell population seemed not to be affected by
the absence of MCs because no significant differences were ob-
served between B6 and KitW-sh mice (Fig. 5A). In the bone marrow
(Fig. 5B), the percentage of CD19+IL-10+ cells was 30% lower in
KitW-sh than in WT mice, but this difference was not statisti-
cally significant. In the peritoneum (Fig. 5C) and lymph nodes
(Fig. 5D), MC-deficient KitW-sh mice had significantly lower
proportions (a 36 and 33% reduction, respectively) of IL-10–
competent B cells than WT controls.
To test whether the observed differences in the percentages of
IL-10–competent B cells between B6 and KitW-sh mice were truly
due to the absence of MCs, we reconstituted KitW-sh mice by i.p.
injection of in vitro differentiated MCs obtained from B6 mice
(BMMC i.p. KitW-sh). As shown in Fig. 5, the decrease in the
proportion of IL-10+ B cells was at least partly corrected in all
tissues analyzed of BMMC-reconstituted KitW-sh mice with the
exception of the peritoneum, where reconstituted MCs failed to
restore the IL-10–competent B cell population as the percentage
of CD19+IL-10+ cells remained significantly lower than in WT
mice.
To further investigate the lack of response of peritoneal B cells
to MCs, we reproduced the reconstitution experiment in vitro
by performing a coculture of peritoneal B cells and MCs, and
subsequently analyzing the effect on the IL-10–competent B
cell population. Peritoneal cells were isolated from both B6 and
KitW-sh mice, and B cells were partially purified and cultured for
48 h with MCs. Thus, the percentages of IL-10–competent B cells
in the cocultures were compared with those within freshly isolated
peritoneal cells of B6 and KitW-sh mice. As shown in Fig. 6A,
in vitro MCs also failed to induce the expansion of CD19+IL-10+
cells from the total population of peritoneal B lymphocytes, de-
rived from either MC-deficient or -sufficient mice. The cocultures
actually yielded decreased percentages of CD19+IL-10+ cells,
although the differences were not statistically significant (Fig. 6A,
right histograms): for B cells isolated from B6 mice, the propor-
tion of CD19+IL-10+ cells decreased from 37.1% (66.2) to 20.7%
(67.0); similarly, B lymphocytes obtained from KitW-sh mice
showed a 36% reduction in IL-10+ B cells after coculture with
MCs.
The different response of peritoneal B cells to MCs could be
because of the specific and peculiar properties of the different B cell
subsets present in this site, and because of their different and selective
capacity to respond to MC-driven stimuli. The peritoneal cavity is
characterized by the presence of two distinct B cell populations, B-1
and B-2, which differ for their developmental origin, anatomical
localization, and functional characteristics (28). Therefore, we next
investigated whether the different B cell subsets present in the
peritoneal cavity responded differently to MCs, in terms of IL-10
competence. The partially purified peritoneal B cell population was
cultured for 48 h with MCs. Then IL-10–competent B cells were
quantified after the 5-h in vitro stimulation with LPIM, and the anti-
CD5 or anti-CD23 Abs were added to the cell-surface staining
mixture to distinguish B-1a (CD5+) from B-1b and B-2 (CD52)
cells or B-2 (CD23+) from B-1a and B-1b (CD232) cells. Consis-
tent with what was previously reported by Maseda and coworkers
(29), we observed that the percentage of B lymphocytes induced to
produce IL-10 was higher among B-1a compared with B-1b and
B-2 cells (Fig. 6B, 6C, left panels). Interestingly, the coculture with
MCs led to a reduction of the percentage of B cells that responded
FIGURE 2. MC-induced, IL-10–competent B cells express markers
typical of T2-MZP cells. (A) B cells were cultured with MCs and, after
LPIM stimulation, were stained with anti-CD19, CD1d, CD5, and IL-10
Abs. Zebra plots for one representative experiment are shown together
with the percentages of IL-10+ and IL-102 B cells that display one of the
four phenotypes defined by the differential expression of CD1d and CD5.
MCs and dead cells were excluded from the analysis using the CD19
versus Live/Dead dot plot, as in Fig. 1A. Histograms show average per-
centages (6SEM) of IL-10+ or IL-102 cells, with a CD1d2CD52, CD1d+
CD52, CD1d+CD5+, or CD1d2CD5+ phenotype from n = 4 experiments.
(B) Expression of CD21 and CD23 was assessed on both IL-10+ and IL-
102 B cells under the conditions described earlier. Zebra plots are repre-
sentative of n = 3 experiments and show the distribution of total IL-10+ and
IL-102 B cells among the subsets defined by CD19 and CD21 or CD19
and CD23 expression.
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FIGURE 3. The CD40L-CD40 axis is involved in MC-induced expansion of IL-10–competent B cells. (A) B cells were cultured with IgE-sensitized or
nonsensitized MCs in the presence or absence of a transwell (TW). (B) Flow cytometry analysis of CD40L expression on WTand Cd40l2/2MCs. (C) Time-
lapse bright-field video microscopy images showing MC–B cell conjugates. Equal numbers of MCs and B cells were seeded onto glass-bottom Petri dishes,
and conjugate formation between the two cell types was monitored for 30 min. The Leica AF6000LX system (microscope: DMI6000 B; camera:
DFC350FX; software: LAS AF) was used. Original magnification340. Scale bar, 10 mm. Histograms represent mean (6SEM) percentages of either WTor
Cd40l2/2 MCs interacting with B cells from, respectively, n = 5 and n = 4 experiments. Cell-contact formation was analyzed at 1, 5, or 20 min from the
beginning of coculture. (D) B cells were cultured with either IgE-sensitized or nonsensitized MCs in the presence or absence of an ascites containing the
anti-CD40L blocking Ab (a-CD40L Ab) or of the CD40L isotype control Ab, mouse IgG (isotype Ab). (E) B cells were cultured with either IgE-sensitized
or nonsensitized MCs obtained by in vitro differentiation of bone marrow precursor cells from WT (MC WT) or CD40L-deficient (MC Cd40l2/2) mice.
Representative dot plots in (A), (D), and (E) refer to 48-h B–MC cocultures, with LPIM addition during the last 5 h, and show the percentage of IL-10+ cells
among total viable CD19+ cells. MCs and dead cells were excluded from the analysis using the CD19 versus Live/Dead dot plot, as in Fig. 1A. Bar graphs
indicate mean (6SEM) percentages from at least three experiments for each condition. *p , 0.05, **p , 0.01.
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to LPIM stimulation, regardless of the B cell subset analyzed. In-
deed, as shown in the representative experiment in Fig. 6B, the
percentage of CD19+IL-10+ cells decreased from 70.6 to 12.3%
among CD19+CD5+ cells and from 30.6 to 7.1% among CD19+
CD52 cells. A similar result was obtained comparing the CD19+
CD23+ and CD19+CD232 populations (Fig. 6C). Thus, it appears
that MCs not only are unable to restore the levels of IL-10–com-
petent B cells in adult KitW-sh mice, but may actually negatively
interfere with the induction of IL-10–competent B cells of all
subsets in this compartment in both WT and KitW-sh mice.
MCs finely regulate the IL-10–competent B cell population in
the gut microenvironment
The observation that certain anatomical sites of KitW-sh mice
present a deficiency of IL-10–competent B cells reveals a novel
and intriguing role of MCs in the regulation of IL-10–competent
B cell differentiation in vivo. Because B cells were shown to play
a critical role in different models of autoimmune disease and
chronic inflammation (11), we decided to further investigate the
effect of MC deficiency on IL-10–competent B cell biology in
a mouse model of intestinal inflammation. The choice of the gut
FIGURE 4. MC-derived exosomes display CD40L and
induce expansion of IL-10–competent B cells. (A) MCs
were cultured in exosome-depleted medium for 48 h,
before collection of supernatants and purification of exo-
somes. Purified exosomes secreted by equal amounts (1 3
106) of nonsensitized (MC) or IgE-Ag–stimulated (MC/
IgE-Ag) MCs were analyzed by immunoblotting for the
presence of Hsc70, Hsp60, ATP5B, and TBP proteins.
Isolated exosomes were confirmed by enrichment of the
exosome markers Hsp60 and Hsc70, and by the absence of
the nuclear marker TBP and of the mitochondrial marker
ATP5B. A total of 1 3 106 MCs was lysed and used for
comparison. (B) Exosome–bead complexes deriving from
supernatants of B cells (B), nonsensitized MCs (MC), and
B–MC cocultures (B+MC) are identified by forward light
scatter (FSC) and side scatter (SSC) properties. CD9 and
CD40L expression was analyzed on exosomes identified
on the basis of their morphological properties. Dot plots
are representative of n = 2 experiments. (C) Percentages of
IL-10+ cells before and after treatment with MC-CM, in
the presence or absence of the anti-CD40L blocking Ab
(a-CD40L Ab) or of its isotype control Ab (isotype Ab).
Bar graphs indicate mean (6 SEM) percentages from
n = 4 experiments. *p , 0.05.
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microenvironment was due to the fact that the colon represents an
anatomical site in which the B–MC interaction is likely to occur
(Supplemental Fig. 3), especially in an inflammatory setting (13).
Moreover, the differentiation of Bregs actively producing IL-10
has been described in this organ (30).
First, we confirmed the ability of MCs to affect IL-10–competent
B cells in a normal intestinal microenvironment. Although in this
condition the proportion of CD19+IL10+ cells present among the
enriched lymphocyte population of the colonic LP is lower com-
pared with other mouse organs, MCs were still able to augment
the percentage of IL-10–competent B cells in a 48-h coculture
assay. After the 5-h in vitro stimulation with LPIM, only 0.8% of
the B cells present among the enriched lymphocyte population of
the LP responded expressing IL-10, but this percentage is doubled
after coculture with MCs (Fig. 7A). This in vitro finding was
further validated by looking at the presence of IL-10–producing
B cells in colon sections of WT and KitW-sh mice by in situ double
immunofluorescence. As a control, the same experiment was
performed in specimens of KitW-sh mice that were i.p. recon-
stituted with WT MCs and in which MC reconstitution was
checked by analyzing the distribution of MCs in the colon 8–10
wk after adoptive transfer of BMMCs (Supplemental Fig. 4). As
shown in Fig. 7B, WT mice had more B cells positively stained for
IL-10 compared with KitW-sh mice. Reconstitution of KitW-sh mice
with WT BMMCs significantly increased the number of IL-10–
producing B cells relative to KitW-sh mice, but it did not com-
pletely restore the number of such cells to the levels of WT mice.
Interestingly, the same effect was not obtained by reconstituting
KitW-sh mice with Cd40l2/2 BMMCs, further supporting the evi-
dence that MC-provided CD40L is an important poising signal for
IL-10 competence in B cells.
We then examined the effect of the absence of MCs on IL-10–
producing B cells in the context of DSS-induced intestinal in-
flammation. Yanaba and coworkers (31) have previously shown
that during DSS-induced intestinal injury, IL-10 expression was
enhanced in splenic B cells, but not in B cells from the intestinal
LP. Accordingly, we found a higher number of B cells positively
stained for IL-10 in colon samples of untreated WT mice than of
WT mice sacrificed in the acute phase of inflammation that is 10 d
after initiation of DSS administration (day 10). This result was not
dependent on MCs because the same outcome was observed also
in KitW-sh mice (Fig. 7C, upper and middle panels). Interestingly,
the number of IL-10–producing B cells began to increase in WT
mice 7 d after DSS withdrawal (day 17), suggesting that this Breg
population might be expanded in the colon or recruited from other
anatomical sites during the recovery phase to resolve inflamma-
tion. Notably, this process was dependent on MCs because no
increase was observed at day 17 in colon samples of KitW-sh mice
(Fig. 7C, lower panels).
Discussion
It is now widely accepted that B cells can exert a regulatory role in
autoimmunity, inflammation, and infection, and that IL-10 pro-
duction is pivotal to Breg-mediated tolerance (11). B cells that
FIGURE 5. MC-deficient mice present
lower frequencies of IL-10–competent B
cells in selected organs. Cells from spleen
(A), bone marrow (B), peritoneum (C), and
lymph nodes (D) of WT (B6, n = 7) and
MC-deficient (KitW-sh, n = 7) mice were
cultured with LPIM for 5 h before staining
for IL-10. The same experiment was per-
formed in KitW-sh mice in which the MC
population was reconstituted by i.p. injec-
tion of in vitro differentiated BMMCs de-
rived from B6 mice (BMMC i.p. KitW-sh,
n = 4). Dot plots from one representative
experiment show frequencies of IL-10+
cells among total viable B cells within the
indicated gates. Dead cells were excluded
from the analysis using the CD19 versus
Live/Dead dot plot (data not shown). Bar
graphs indicate mean (6 SEM) percentages
of IL-10+ B cells from all mice analyzed.
*p , 0.05, **p , 0.01.
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produce IL-10 are found at different anatomical sites where they
exert their suppressive function after encountering an appropriate
and context-specific signal. This response can be mimicked
in vitro by the short-term stimulation with LPS, PMA, and ion-
omycin, which promotes Il-10 expression only in poised B cells
already competent for cytokine production, allowing their detec-
tion ex vivo (10). Over the past decade, a considerable effort has
been made toward identification of signals that induce IL-10–
FIGURE 6. MCs do not induce the expansion of mature peritoneal IL-10–competent B cells. (A) The frequency of IL-10+ B cells was analyzed among
the partially purified B cell peritoneal population of B6 and KitW-sh mice (peritoneal B pre-coculture) and in the same B cells cultured with nonsensitized
MCs (peritoneal B+MC). In all conditions, LPIM was added during the last 5 h of culture. Dot plots from one representative experiment show the per-
centages of IL-10+ B cells within the indicated gates. Non-B and dead cells were excluded from the analysis using the CD19 versus Live/Dead dot plot (data
not shown). Samples colored with the rat IgG2b isotype control Ab served as negative controls. Bar graphs indicate mean (6 SEM) percentages of IL-10+
cells among total B cells from n = 3 experiments. (B and C) Frequency of IL-10–competent B cells among B-1a, B-1b, and B-2 peritoneal cells, before and
after coculture with MCs. The cell-surface CD5 was used to distinguish B-1a from B-1b+B-2 cells (B), whereas CD23 allowed to discriminate between B-2
and B-1a+B-1b cells (C). Reported plots are representative of n = 3 (B) and n = 2 (C) experiments.
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FIGURE 7. MCs regulate the IL-10–competent B cell population in the gut microenvironment. (A) IL-10–competent B cells were analyzed among the
freshly isolated LP cell population (LP B pre-coculture) and among the same cell population cultured for 48 h with nonsensitized MCs (LP B+MC). In all
conditions, LPIM was added for the last 5 h of culture. Dot plots for one representative experiment are shown. Only viable B cells were analyzed for IL-10
staining, and a perfectly matched isotype control was used to discriminate IL-10+ from IL-102 B cells. Bar graphs indicate mean (6SEM) percentages of
IL-10+ cells among total B cells (n = 3). *p , 0.05. (B) Immunofluorescence analysis of B cells positively stained for IL-10 on formalin-fixed, paraffin-
embedded colon sections of WT (B6) and MC-deficient (KitW-sh) mice and MC-deficient mice reconstituted with BMMCs from either B6 (BMMC WT i.p.
KitW-sh) or CD40L-deficient (BMMC Cd40l2/2 i.p. KitW-sh) mice. Scale bars, 100 mm. Bar graphs indicate mean (6 SEM) numbers of CD45R+IL-10+ cells
for one of two independent experiments. B cells positively stained for IL-10 were detected and counted out of five 3400 high-power microscopic fields in
each case. *p , 0.05, **p , 0.01, ***p , 0.001. (C) Immunofluorescence analysis of IL-10+ B cells on formalin-fixed, paraffin-embedded colon sections
of WT (B6) and MC-deficient (KitW-sh) mice at steady-state (day 0), during acute DSS-induced intestinal inflammation (day 10), or 7 d after DSS
withdrawal (day 17; recovery from inflammation). Scale bars, 50 mm. Bar graphs indicate mean (6 SEM) numbers of CD45R+IL-10+ cells for one of two
independent experiments. B cells stained for IL-10 were detected and counted out of four 3400 high-power microscopic fields in each case. *p , 0.05. (B
and C) Slides were evaluated using a Leica DMI6000 microscope, and microphotographs were collected using a Leica DFC350FX digital camera. Original
magnification 3200. Red represents CD45R; green represents IL-10.
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competent B cells in vivo (12). Nonetheless, little is known about
how the cell types promote IL-10–competent B cell expansion.
In this article, we show that MCs contribute to the expansion
of IL-10–competent splenic B cells in vitro. The proportion of
CD19+IL-10+ cells was significantly increased after culturing
B cells with MCs, and proliferation assays demonstrated that MC-
derived signals promote the preferential proliferation of IL-10–
competent B cells with respect to other B cell subsets. However,
a process of de novo differentiation of IL-10–competent B cells
cannot be excluded. Although MCs induced the expansion of IL-
10–competent B cells, they did not enhance the overall production
of the cytokine. IL-10 mRNA and protein levels in B lymphocytes
were not increased in the presence of MCs. This is not unexpected
because the expansion of IL-10–competent B cells and the pro-
duction of IL-10 are two distinct processes, differentially regu-
lated. A superb example comes from direct CD40 activation of
B cells: although CD40 signaling promotes an increase in the
proportion of IL-10–competent B cells, it does not itself induce
IL-10 secretion (32). Thus, consistent with our findings, the signals
provided by MCs seem to be preparatory in nature, instructing the
B cell to become competent for a suppressive function when en-
countering an appropriate and context-specific second signal.
We show that CD40L on MCs is important for IL-10–competent
B cell expansion because the presence of anti-CD40L blocking Ab
or of Cd40l2/2MCs led to a significant reduction of CD19+IL-10+
cells in the cocultures. However, it is also clear that other
membrane-bound or soluble factors are likely to contribute to this
expansion. MCs release cytokines known to affect important
physiological functions such as B cell growth, differentiation, and
Ig class switching (33, 34). Moreover, MCs can release leukotri-
ene B4, to which it has recently been attributed a role in the
generation of tumor-evoked Bregs (35). These multiple factors
constitute fertile ground for further investigation. The role of
exosomes in cell–cell communication is noteworthy (36), and the
finding that MCs produce exosomes suggests that this may be an
important mechanism by which MCs communicate to other cells.
Importantly, we show that MC-derived exosomes express CD40L
and contribute to the expansion of IL-10–competent B cells.
Taking advantage of the KitW-sh murine model of MC deficiency,
we investigated the role of MCs on IL-10–competent B cell dif-
ferentiation and maturation in vivo. If on one hand our results
argue that MCs are involved in these processes (KitW-sh mice had
significant lower percentages of CD19+IL-10+ cells in the colon,
peritoneum, and lymph nodes compared with WT mice), then on
the other hand they revealed the complexity of the in vivo regu-
lation of IL-10–competent B cell differentiation, which appeared
to be tissue specific. No differences were observed in the spleen,
a site in which B–MC interactions are less likely and where other
immune cell types may play specific inductive functions, com-
pensating the role of MCs. The IL-10–competent B cell deficiency
in the peritoneum of KitW-sh mice is peculiar in that MC recon-
stitution in adult mice does not restore normal percentages of
these cells. This difference is not due to the selective sensitivity of
the B-1 versus the B-2 cell subsets to MCs because B cells that
belong to both subsets appear insensitive to the inductive signals
from MCs. Given the developmental features of this immuno-
logical site (the peritoneum is populated early during ontogenesis
and the resident B cell population is mainly self-replenishing)
(37), it is still possible that MCs influence the development of
IL-10–competent B cells earlier in life and that the deficiency
observed in adult KitW-sh mice is the result of a defect during
ontogenesis. Nonetheless, once B cells have developed and es-
tablished themselves in the peritoneum, their interaction with
MCs does not lead to the expansion of IL-10–competent B cells.
Thus, the cross talk between peritoneal B cells and MCs appears
to produce different effects compared with the other organs ana-
lyzed. Again, this probably reflects the peculiar immunological
features of this compartment and the specific functions of peri-
toneal MCs and B cells within.
Finally, we observed that the IL-10–producing B cell population
is significantly reduced in the colon of KitW-sh mice and that the
population of IL-10–competent B cells resident in the LP responds
to the inductive signals of MCs as CD19+IL10+ cells are expanded
when cocultured in vitro with MCs. Moreover, MCs could play
a role in expansion of IL-10–competent B cells resident in the LP
and/or in the recruitment of circulating IL-10–competent B cells
to this site because in KitW-sh mice we did not observe an increase
of these cells during the resolution phase of DSS-induced intes-
tinal inflammation. The function of IL-10–producing B cells in
this organ represents a key mechanism for the maintenance of gut
homeostasis and for the control of the immune response against
Ags (38). MC regulation of IL-10–competent B cells in the colon
contributes to this homeostatic process, and the alteration of this
mechanism could play a role in pathological conditions such as
chronic inflammation and cancer.
In conclusion, for the first time, to our knowledge, we provide the
evidence of a complex cross talk between MCs and B cells that is
important for the expansion and differentiation of IL-10–competent
B cells. We show that MCs are able to modulate the IL-10–com-
petent B cell population according to the specific tissue microen-
vironment, and we provide evidence that in the absence of MCs the
proportions of IL-10–competent B cells are significantly reduced in
several immunological sites, both under homeostatic conditions and
at resolution of inflammation.
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